Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $8 | $0 | $0 |
| % Growth | 29.9% | – | – | – |
| Cost of Goods Sold | $8 | $5 | $0 | $0 |
| Gross Profit | $2 | $3 | $0 | $0 |
| % Margin | 23.1% | 39% | – | – |
| R&D Expenses | $40 | $87 | $82 | $69 |
| G&A Expenses | $3 | $35 | $30 | $23 |
| SG&A Expenses | $40 | $35 | $30 | $23 |
| Sales & Mktg Exp. | $37 | $0 | $0 | $0 |
| Other Operating Expenses | $58 | $0 | $0 | $0 |
| Operating Expenses | $139 | $121 | $112 | $92 |
| Operating Income | -$137 | -$118 | -$112 | -$92 |
| % Margin | -1,354.3% | -1,523.9% | – | – |
| Other Income/Exp. Net | $7 | $2 | $2 | $0 |
| Pre-Tax Income | -$130 | -$117 | -$110 | -$92 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$130 | -$117 | -$110 | -$92 |
| % Margin | -1,288.3% | -1,501.8% | – | – |
| EPS | -176.6 | -6,368.84 | -811.68 | -163,968 |
| % Growth | 97.2% | -684.6% | 99.5% | – |
| EPS Diluted | -176.6 | -6,368.84 | -811.68 | -163,968 |
| Weighted Avg Shares Out | 2 | 2 | 3 | 0 |
| Weighted Avg Shares Out Dil | 2 | 2 | 3 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $4 | $1 | $0 |
| EBITDA | -$74 | -$114 | -$111 | -$92 |
| % Margin | -736.3% | -1,468.7% | – | – |